Re‐irradiation (re‐RT) for recurrent head and neck cancer (HNC) can be potentially curative but is constrained by significant toxicity. Proton therapy may improve the therapeutic ratio. This multicenter phase 2 trial evaluated the safety and efficacy of proton re‐RT in patients with HNC.
E. Dee, C. A. Barker, N. Kalman et al.· Cancer· 0 citations
This cohort study describes 5-year outcomes following a de-escalated 30-Gy elective nodal irradiation regimen during definitive concurrent chemoradiotherapy among patients with human papillomavirus–associated oropharyngeal carcinoma.
A. Safavi, E. Dee, C. Tsai et al.· JAMA Oncology· 0 citations
This retrospective study compared the efficacy and toxicity of concurrent triweekly versus weekly cisplatin in patients with previously untreated, biopsy-proven NPC who received definitive CRT followed by adjuvant chemotherapy. Patients with distant metastasis, Karnofsky Performance Status < 80, induction chemotherapy,...
Hao-Shen Cheng, Irini Yacoub, W. Wong et al.· International Journal of Can...· 0 citations
Pancreatic cancer (PC) is largely refractory to immune checkpoint blockade (ICB), although homologous recombination-deficient (HRD) tumors may derive benefit. In the POLAR trial of maintenance pembrolizumab plus olaparib after platinum-based chemotherapy for metastatic PC, responses remained heterogeneous. To define de...
M. Hilmi, J. Schoenfeld, Wilson H. McKerrow et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.